Adalank
A vendor-formulated hybrid research peptide fusing Adamax-style cognitive enhancement with Selank-style anxiolysis in a single molecule.
Adalank is a hybrid research peptide combining structural elements of Adamax (an adamantyl-modified Semax analog) with Selank (the Pro-Gly-Pro tuftsin-derived anxiolytic). Marketed around 2022-2024 as a single-molecule replacement for parallel Adamax + Selank protocols, it aims to deliver an 'alert calm' state — motivation and cognitive clarity layered onto anxiolysis without sedation. There is no peer-reviewed literature for Adalank itself; PubMed returns zero hits, and all pharmacological claims are extrapolated from its constituent compounds.
Class
Hybrid research peptide (Adamax adamantyl-Semax analog fused to Selank heptapeptide)
Half-life
~72 hours functional receptor binding (extrapolated from Adamax kinetic claims); serum half-life unknown, no published pharmacokinetic data
Routes
Intranasal, Subcutaneous
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Combined cognition and anxiolysis
Delivers Adamax-tier cognitive enhancement layered onto Selank-tier anxiolysis in one molecule, targeting focus, motivation and reduced anxiety simultaneously. The dual profile is inferred from the constituent compounds rather than direct study of the hybrid.
BDNF / TrkB upregulation
The Adamax component is hypothesized to upregulate brain-derived neurotrophic factor in the hippocampus and modulate TrkB receptor sensitivity, the proposed basis for sustained focus and memory consolidation. Evidence is extrapolated from Semax and adamantane-CNS literature.
GABAergic calm without sedation
The Selank moiety carries documented GABAergic anxiolytic activity that reduces anxiety without the sedation of benzodiazepines. Selank's parent showed no benzodiazepine-like tolerance or withdrawal in Russian outpatient trials.
Dopaminergic drive
Adamax reportedly modulates dopamine D2 receptor sensitivity in motivation circuits, contributing to a 'drive' and reward response distinct from but overlapping with stimulant-class effects.
Extended dosing interval
Community protocols cite roughly 72-hour functional receptor binding, supporting once- or twice-daily and even every-other-day schedules. This duration claim is plausible from the adamantyl group but unverified by independent measurement.
Improved blood-brain-barrier penetration
The adamantyl cage inherited from Adamax is the same lipophilic structure used in amantadine and memantine to improve BBB permeability, hypothesized to lower the effective peripheral dose. No direct pharmacokinetic comparison versus Adamax or Selank alone has been published.
Subjective 'alert calm'
Users report motivation without anxiety and focus without overstimulation — a state resembling NA-Semax + Selank or P-21 + Selank stacks consolidated into a single molecule.
Mechanism
How it works
Adalank is a two-part molecule, and its proposed activity mirrors the mechanisms of its parents. The Adamax side is hypothesized to upregulate brain-derived neurotrophic factor (BDNF) in the hippocampus and modulate TrkB receptor sensitivity — the proposed basis for the cognitive-enhancement signal (sustained focus, memory consolidation, motivation) seen in community protocols. Adamax is also reported to modulate dopamine D2 receptor sensitivity in ventral tegmental area and nucleus accumbens motivation circuits, contributing to the dopaminergic 'drive' and reward response some users describe.
The Selank moiety contributes Selank's documented anxiolytic profile: GABAergic modulation without sedation, hippocampal BDNF upregulation (overlapping with the Adamax mechanism) and serotonergic/enkephalin-like effects. In published Russian outpatient trials, Selank did not produce benzodiazepine-like tolerance or withdrawal — a central selling point of the family. Selank's C-terminal Pro-Gly-Pro fragment derives from the immunomodulatory peptide tuftsin, giving it tuftsin-like cytokine-balancing activity, though whether this carries over to the hybrid depends on the specific bond chemistry used by the vendor.
The adamantyl group inherited from the Adamax side is the same lipophilic cage structure used in amantadine and memantine to improve blood-brain-barrier permeability. This is hypothesized to lower the effective peripheral dose required for central effects and to extend receptor binding, with community protocols citing roughly 72-hour functional duration after a single dose. No direct pharmacokinetic comparison versus Adamax or Selank alone has been published, so these delivery and duration claims remain plausible but unverified.
The combined subjective result reported by users is an 'alert calm' state — Adamax-driven motivation and cognitive clarity layered onto Selank-driven anxiolysis. It is important to note that Adalank has zero direct studies; every mechanism above is inferred from the Semax, Selank and adamantane-CNS literature rather than measured in the hybrid molecule itself.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Supplied lyophilized in glass vials; reconstitute with bacteriostatic water (0.9% benzyl alcohol preserved), not plain sterile water if multi-day use is planned. Example for a 10 mg vial: add 2 mL bacteriostatic water for 5 mg/mL (500 mcg per 0.1 mL / 10 IU on a U-100 insulin syringe), or add 5 mL for 2 mg/mL (200 mcg per 0.1 mL / 4 IU). For intranasal use, dilute further to 100-200 mcg per spray depending on the applicator's volume per actuation. Swirl gently, never shake; discard cloudy or discolored solution.
Beginner
- Dose
- 200-400 mcg per day
- Frequency
- Once daily
- Timing
- Morning or early afternoon
- Duration
- 14 days
- Route
- Intranasal
Assess tolerance and note the baseline subjective shift; do not expect a stimulant-like first-day effect.
Intermediate
- Dose
- 400-800 mcg per day
- Frequency
- Once or twice daily
- Timing
- Morning or early afternoon
- Duration
- 21-30 days on / 7-14 days off
- Route
- Intranasal or subcutaneous
Therapeutic dosing where most users report peak subjective effects in weeks 2-3.
Advanced
- Dose
- 800-1200 mcg per day
- Frequency
- Twice daily
- Timing
- Morning and early afternoon; avoid late-evening dosing
- Duration
- 30-day cycles, 14-day washout
- Route
- Intranasal or subcutaneous
Optimization for non-responders; not required for most users. No additional benefit reported past 1200 mcg/day.
- Dosing follows a Selank/Adamax-style pattern — micrograms, not milligrams. Double-check vial concentration before reconstitution, as the hybrid can be sold at concentrations between Selank (5-10 mg vials) and Adamax (2-10 mg vials).
- Titration: Week 1 at 200-400 mcg/day to assess tolerance; Weeks 2-3 at 400-800 mcg/day for peak effects; optional Week 4 at 800-1200 mcg/day for non-responders; then a 7-14 day washout for receptor resensitization.
- Effects build over 7-10 days, peak in weeks 2-3, and taper over 1-2 weeks after the last dose. Every-other-day protocols are also documented given the claimed ~72-hour receptor binding.
- Cycle 21-30 days on with 7-14 day washouts; avoid chronic continuous dosing to limit theoretical receptor desensitization at both the BDNF/TrkB and GABAergic ends.
- Avoid late-evening dosing (the Adamax component can disrupt sleep at higher doses) and avoid combining at full doses with overlapping family compounds (Semax, Selank, Adamax, P-21).
- Storage: lyophilized vials refrigerate or freeze (stable 12+ months sealed); reconstituted solution refrigerate and use within 28 days, do not freeze.
Combinations
Stacking & blends
Adalank + Cerebrolysin
Neurotrophic amplification
Cerebrolysin's peptide fragment mix layers on top of Adalank's BDNF/TrkB signal without direct receptor overlap.
Adalank + Dihexa
Synaptogenesis
Dihexa is an angiotensin-IV-derived synaptogenic peptide acting via HGF signaling, complementary to the BDNF and GABA pathways Adalank already covers.
Adalank + BPC-157
Neuroprotective baseline
BPC-157 provides dopaminergic system stabilization and neuroprotection with no mechanistic overlap with the cognitive enhancer.
Adalank + Methylene Blue
General cognitive support
Methylene Blue acts as a mitochondrial cofactor, adding a different mechanism layer beneath Adalank's receptor-level effects.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy and lactation (no safety data)
- Active psychiatric instability such as acute mania or psychosis (dopaminergic component may exacerbate)
- Pediatric use (uncharacterized in any age group below adult)
- Known hypersensitivity to peptide injections or any constituent peptide
- Bipolar disorder, any phase (D2 modulation may destabilize mood cycling) — caution
- Uncontrolled hypertension (reports of mild BP elevation) — caution
- Concurrent benzodiazepines or other GABAergic sedatives (additive effects) — caution
- Concurrent MAOI therapy or stimulants/amphetamines/methylphenidate (dopaminergic interaction/load) — caution
- Recent head trauma and fragile sleep disorders — caution
No reported serious adverse events appear in community datasets, but this reflects unregulated underreporting rather than formal safety clearance. No long-term safety data exists; multi-month and multi-year exposure consequences are entirely uncharacterized, and cycling protocols are a precautionary mitigation rather than a validated safe-use pattern. If side effects emerge, halve the dose and restrict to morning dosing for headache or insomnia, switch route or discontinue for persistent nasal irritation, and discontinue for mood instability or BP elevation.
FAQ
Adalank — common questions
What's the difference between Adalank and just running Adamax + Selank together?
Pharmacologically the goal is the same — Adamax's cognitive and motivational effects layered onto Selank's anxiolysis. The hybrid is sold on a convenience argument (one product, one protocol) and a claimed pharmacokinetic argument (the adamantyl group extends receptor binding). No head-to-head data has been published, so treat the convenience as real and the PK advantage as plausible but unverified.
Why are there no PubMed studies for Adalank?
Adalank is a vendor-formulated research peptide, not a clinical drug, and was never developed in an academic pipeline. Its components have separate literature bases, but the hybrid itself has zero direct publications. Effects, dosing and safety are inferred entirely from the constituent compounds and community protocols.
Is Adalank the same thing as N-acetyl-Selank-amidate?
Sometimes — vendors are inconsistent. Some sell 'Adalank' as the Adamax + Selank hybrid described here; others use the same name for N-acetyl-Selank-amidate (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, ~792.9 Da), which is just Selank with acetyl and amide stability caps and no adamantane group. Confirm with the supplier, because the dosing, half-life and mechanism differ meaningfully.
Intranasal or subcutaneous?
Both are documented. Intranasal is more common for users who already use Selank or Semax that way and gives more controlled dose titration. Subcutaneous is favored for larger or more lipophilic products that absorb poorly through nasal mucosa and gives faster onset. Both routes reach central targets without dramatically changing the effect profile.
How long does a cycle last and why the washouts?
A typical cycle is 21-30 days on with 7-14 days off. The washout is precautionary because Adalank modulates BDNF/TrkB/D2 (Adamax side) and GABA/serotonergic systems (Selank side), and continuous stimulation of any single receptor system risks desensitization. There is no formal data establishing the optimal cycle length — these are community-developed precautions.
Can Adalank be used long-term?
There is no long-term safety data at all. Multi-month and multi-year exposure consequences are uncharacterized, and cycling protocols are a precautionary mitigation rather than validation of safety. If used across multiple cycles, monitor for mood changes, sleep disruption and cardiovascular shifts.
What does Adalank feel like subjectively?
Most users report an 'alert calm' state — focused and motivated without stimulant-type anxiety, and calm without GABAergic sedation. Effects build over 7-10 days, peak in weeks 2-3, and taper over 1-2 weeks after the last dose, consistent with the claimed ~72-hour receptor binding window.
Are the '30-100x more potent than Selank or Semax' claims real?
No published source substantiates the potency multipliers found on vendor sites; treat them as marketing. Likewise, 'better BBB penetration than Adamax or Selank alone' is plausible from adamantane chemistry but not directly measured, and 'clinically proven anxiolysis' is false for Adalank itself — only the Selank parent holds Russian regulatory approval.
